Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 9;11(1):58.
doi: 10.1186/s12920-018-0375-5.

Comprehensive genomic diagnosis of non-syndromic and syndromic hereditary hearing loss in Spanish patients

Affiliations

Comprehensive genomic diagnosis of non-syndromic and syndromic hereditary hearing loss in Spanish patients

Rubén Cabanillas et al. BMC Med Genomics. .

Abstract

Background: Sensorineural hearing loss (SNHL) is the most common sensory impairment. Comprehensive next-generation sequencing (NGS) has become the standard for the etiological diagnosis of early-onset SNHL. However, accurate selection of target genomic regions (gene panel/exome/genome), analytical performance and variant interpretation remain relevant difficulties for its clinical implementation.

Methods: We developed a novel NGS panel with 199 genes associated with non-syndromic and/or syndromic SNHL. We evaluated the analytical sensitivity and specificity of the panel on 1624 known single nucleotide variants (SNVs) and indels on a mixture of genomic DNA from 10 previously characterized lymphoblastoid cell lines, and analyzed 50 Spanish patients with presumed hereditary SNHL not caused by GJB2/GJB6, OTOF nor MT-RNR1 mutations.

Results: The analytical sensitivity of the test to detect SNVs and indels on the DNA mixture from the cell lines was > 99.5%, with a specificity > 99.9%. The diagnostic yield on the SNHL patients was 42% (21/50): 47.6% (10/21) with autosomal recessive inheritance pattern (BSND, CDH23, MYO15A, STRC [n = 2], USH2A [n = 3], RDX, SLC26A4); 38.1% (8/21) autosomal dominant (ACTG1 [n = 3; 2 de novo], CHD7, GATA3 [de novo], MITF, P2RX2, SOX10), and 14.3% (3/21) X-linked (COL4A5 [de novo], POU3F4, PRPS1). 46.9% of causative variants (15/32) were not in the databases. 28.6% of genetically diagnosed cases (6/21) had previously undetected syndromes (Barakat, Usher type 2A [n = 3] and Waardenburg [n = 2]). 19% of genetic diagnoses (4/21) were attributable to large deletions/duplications (STRC deletion [n = 2]; partial CDH23 duplication; RDX exon 2 deletion).

Conclusions: In the era of precision medicine, obtaining an etiologic diagnosis of SNHL is imperative. Here, we contribute to show that, with the right methodology, NGS can be transferred to the clinical practice, boosting the yield of SNHL genetic diagnosis to 50-60% (including GJB2/GJB6 alterations), improving diagnostic/prognostic accuracy, refining genetic and reproductive counseling and revealing clinically relevant undiagnosed syndromes.

Keywords: Diagnostics; Gene panel; Hearing loss; Hereditary; NGS; Precision.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the Comité de Ética de Investigación del Principado de Asturias (research project #75/14). Consent was obtained from all patients or their parents.

Consent for publication

Not applicable.

Competing interests

The following authors are currently employed by IMOMA or DREAMgenics, the companies involved in the development and exploitation of the OTOgenics™ platform: IMOMA: Ru.C. (Physician in Chief), M.D. (Clinical Molecular Geneticist), G.A.C. (Biotechnologist), N.S.D. (Lab. Technician), R.A. (Lab. Technician), Ra.C. (Molecular Biologist) and J.C. (Scientific Director); DREAMgenics: D.C. (Bioinformatitian), P.C.P. (Bioinformatitian) and G.R.O. (Bioinformatitian, C.S.O. and C.E.O.). G.R.O. is a shareholder of DREAMgenics. The other authors declare no conflict of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Presence/absence of total and causative variants in databases. Circles represent total numbers of tier 1 (left) and tier 2 (right) variants (not to scale), their presence in the HGMD professional and/or ClinVar databases (in DBs) or their absence from both databases (not in DBs) at the moment of case evaluation, and the distribution of the 32 variants considered causative of HL within these categories
Fig. 2
Fig. 2
Genetically diagnosed cases explained by variants present in and absent from databases. Sectors represent the percentage of genetically diagnosed cases explained by variants present in (in DBs) or absent from (not in DBs) the HGMD professional and/or ClinVar databases at the moment of case evaluation

References

    1. Alford RL, Arnos KS, Fox M, Lin JW, Palmer CG, Pandya A, Rehm HL, Robin NH, Scott DA, Yoshinaga-Itano C, et al. American College of Medical Genetics and Genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss. Genet Med. 2014;16(4):347–355. doi: 10.1038/gim.2014.2. - DOI - PubMed
    1. Burke WF, Warnecke A, Schoner-Heinisch A, Lesinski-Schiedat A, Maier H, Lenarz T. Prevalence and audiological profiles of GJB2 mutations in a large collective of hearing impaired patients. Hear Res. 2016;333:77–86. doi: 10.1016/j.heares.2016.01.006. - DOI - PubMed
    1. Chan DK, Chang KW. GJB2-associated hearing loss: systematic review of worldwide prevalence, genotype, and auditory phenotype. Laryngoscope. 2014;124(2):E34–E53. doi: 10.1002/lary.24332. - DOI - PubMed
    1. Sabatini LM, Mathews C, Ptak D, Doshi S, Tynan K, Hegde MR, Burke TL, Bossler AD. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: A Report of the Association for Molecular Pathology. J Mol Diagn. 2016;18(3):319–328. doi: 10.1016/j.jmoldx.2015.11.010. - DOI - PMC - PubMed
    1. Shearer AE, Smith RJ. Massively parallel sequencing for genetic diagnosis of hearing loss: the new standard of care. Otolaryngol Head Neck Surg. 2015;153(2):175–182. doi: 10.1177/0194599815591156. - DOI - PMC - PubMed

Publication types